HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering
Rhea-AI Summary
HCW Biologics Inc. (NASDAQ:HCWB) has announced the pricing of its initial public offering (IPO) of 7,000,000 shares at $8.00 per share, aiming for gross proceeds of approximately $56.0 million. The shares are set to trade on the Nasdaq Global Market starting July 20, 2021. The offering is anticipated to close around July 22, 2021, pending customary conditions. An additional 1,050,000 shares may be purchased by underwriters within 45 days. EF Hutton is the sole book-running manager for the offering.
Positive
- Successful pricing of an IPO, raising approximately $56.0 million.
- Trading commencement on Nasdaq expected to enhance visibility and liquidity.
Negative
- Potential shareholder dilution due to the offering of additional shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIRAMAR, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the pricing of an underwritten initial public offering of 7,000,000 shares of common stock at a public offering price of
EF Hutton, division of Benchmark Investments, LLC, is acting as sole book-running manager for the offering. Revere Securities LLC is acting as co-manager for the offering.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 19, 2021. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: EF Hutton, division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@efhuttongroup.com or telephone at (212) 404-7002.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
| Company Contact Rebecca Byam, MBA CPA Chief Financial Officer HCW Biologics Inc. 954-842-2024, Extension 252 rebeccabyam@hcwbiologics.com | Investor Relations Contact Maureen McEnroe, CFA Executive Vice President Tiberend Strategic Advisors, Inc. 212-375-2664 mmcenroe@tiberend.com |